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Drugs activating group III metabotropic glutamate receptors (mGluRs) represent therapeutic alternatives to L-DOPA (L-3,4-
dihydroxyphenylalanine) for the treatment of Parkinson’s disease (PD). Their presynaptic location at GABAergic and glutamatergic
synapses within basal ganglia nuclei provide a critical target to reduce abnormal activities associated with PD. The effects of selective
group III mGluR agonists (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) and L-()-2-amino-4-phosphonobutyric
acid (L-AP4) infused into the globus pallidus (GP) or the substantia nigra pars reticulata (SNr) were thus studied in rat models of PD.
Bilateral infusions ofACPT-I (1, 2.5, and5nmol/l) into theGP fully reverse the severe akinetic deficits producedby 6-hydroxydopamine
nigrostriatal dopamine lesions in a reaction-time task without affecting the performance of controls. Similar results were observed after
L-AP4 (1 nmol) or picrotoxin, a GABAA receptor antagonist, infused into the GP. In addition, intrapallidal ACPT-I counteracts
haloperidol-induced catalepsy. This effect is reversed by concomitant administration of a selective group III receptor antagonist (RS)-
-cyclopropyl-4-phosphonophenylglycine. In contrast, ACPT-I (0.05, 0.1, and 0.25 nmol) infusions into the SNr enhance the lesion-
induced akinetic deficits in control and lesioned rats anddonot reverse haloperidol-induced catalepsy. L-AP4 (0.05 nmol) andpicrotoxin
in the SNr produce the same effects. Together, these results show that activation of group III mGluRs in the GP provides benefits in
parkinsonian rats, presumably by modulating GABAergic neurotransmission. The opposite effects produced by group III mGluR acti-
vation in the SNr, also observed with a selective mGluR8 agonist, support the use of subtype-selective group III mGluR agonists as a
potential antiparkinsonian strategy.
Key words: metabotropic glutamate receptor; 6-hydroxydopamine; Parkinson’s disease; GABAA receptor; substantia nigra; globus
pallidus
Introduction
The progressive loss of midbrain dopamine (DA) neurons is a
primary cause of the hypokinetic symptoms (akinesia and brady-
kinesia) of Parkinson’s disease (PD). The DA denervation of the
striatum leads to an imbalance between dopaminergic and gluta-
matergic transmission in the basal ganglia such that excessive
activity in basal ganglia outflow disruptsmotor control. The clas-
sical L-3,4-dihydroxyphenylalanine (L-DOPA) therapy of PD
provides dramatic palliative benefit but leads tomotor complica-
tion, particularly dyskinesia, after prolonged treatment (Jank-
ovic, 2002). This led to the development of novel pharmacologi-
cal therapeutic targets that bypass the DA system, among which
glutamatergic drugs have previously been highlighted (Conn et
al., 2005).
Because of their modulatory action on glutamate neurotrans-
mission, the metabotropic glutamate receptors (mGluRs) previ-
ously received much attention as potential targets in the treat-
ment of neurodegenerative and psychiatric disorders (Rouse et
al., 2000; Conn et al., 2005). Based on primary sequence, second
messenger coupling and pharmacological profiles, mGluRs are
classified into three subgroups: group I (mGluR1, mGluR5),
group II (mGluR2, mGluR3), and group III (mGluR4, mGluR6,
mGluR7, and mGluR8) (Conn and Pin, 1997). In animal models
of PD, blockade of group I or activation of group II mGluRs
produces beneficial effects on parkinsonian symptoms by reduc-
ing the aberrant firing activity in the basal ganglia (BG) circuitry
(Feeley Kearney and Albin, 2003; Senkowska and Ossowska,
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2003; Conn et al., 2005). Comparatively, less is known about the
therapeutic potential of group III mGluR agonists in animal
models of the disease. Three of the four group III mGluRs
(mGluR4, mGluR7, and mGluR8) are presynaptically localized
on glutamatergic and GABAergic nerve terminals in key struc-
tures of the BG: striatum, globus pallidus (GP), or the substantia
nigra pars reticulata (SNr) (Bradley et al., 1999b; Kosinski et al.,
1999; Corti et al., 2002). Electrophysiological studies conducted
in brain slices elegantly demonstrated that the group III mGluR-
specific agonist L-()-2-amino-4-phosphonobutyric acid (L-
AP4)modulates inhibitory and excitatory transmission in the GP
and the SNr (Wittmann et al., 2001; Marino et al., 2003; Matsui
and Kita, 2003; Valenti et al., 2003). Group III mGluR agonists
have antiparkinsonian actions in reserpine or haloperidol-
treated rats (Marino et al., 2003; Valenti et al., 2003; MacInnes et
al., 2004; Konieczny et al., 2007) and in unilateral
6-hydroxydopamine (6-OHDA)-lesioned rats by improving
forelimb asymmetry and producing contraversive rotation
(Kearney et al., 1998; Zhang andAlbin, 2000; Valenti et al., 2003).
However, the ability of group III mGluR agonists to provide
functional relief in the early symptomatic stage of PD remains to
be investigated. We showed previously that 6-OHDA-induced
lesions of the dorsolateral part of the striatum, reproducing the
prominent denervation of the dorsal and caudal putamen in early
PD, produce consistent deficits in a reaction-time (RT) task in
rats that are related to the akinesia observed in PD patients
(Amalric and Koob, 1987; Amalric et al., 1995). Blockade
of mGluR5 with the selective antagonist 2-methyl-6-(phenyl-
ethynyl)-pyridine was found previously to reverse 6-OHDA-
induced akinesia in the reaction-time task (Breysse et al., 2002).
The effects of intracerebral administration into the GP or the SNr
of group III mGluR agonists (1S,3R,4S)-1-aminocyclopentane-
1,3,4-tricarboxylic acid (ACPT-I) (Acher et al., 1997; Schann et
al., 2006) and L-AP4 were thus tested in the same model of early
PD and against haloperidol-induced catalepsy.
Materials andMethods
Animals
MaleWistar rats (Charles River, L’Arbresle, France), weighing 175–185 g
at the beginning of the experiment, were housed in groups of twoper cage
and maintained in temperature-controlled conditions with a 12 h light/
dark cycle (lights off from 7:00 A.M. to 7:00 P.M.). Rats tested in the RT
task were fed 15–17 g/d of laboratory chow, delivered 3 h after testing
period, so as tomaintain 85% ad libitum feeding body weight.Water was
provided ad libitum. For the catalepsy experiment, water and food were
provided ad libitum. All procedures were conducted in accordance with
the requirements of the French Ministe`re de l’Agriculture et de la Peˆche
De´cret No. 87–848 (October 19, 1987) and the European Communities
council directive of November 24, 1986 (86/609/EEC).
Behavioral procedure
Catalepsy test. Catalepsy was assessed using the bar test (a metal rod
positioned 9 cm above the floor). The time elapsing before the rat
climbed down from the bar was recorded in seconds (with a cutoff time
of 120 s) each 10 min for the 1 h of testing.
Reaction-time task.Eight operant boxes (Campden Instruments, Cam-
bridge, UK) were used for the RT task. Each box was equipped with a
retractable lever, a food magazine and a cue light (2.8 W bulb) located
above the lever corresponding to the response signal. The lever required
a force of 0.7N for switch closure. A house light located on the ceilingwas
turned on at the beginning of the testing session. Each box was placed in
a wooden sound-attenuating cabinet that was ventilated by a low-level
noise fan to reduce outside noise. Food restriction was introduced at the
beginning of training period. Rats were trained daily for 3 months to
quickly release the lever after the visual cue onset presented after four
randomly and equiprobably generated foreperiods (0.5, 0.75, 1.0, or
1.25 s). To be rewarded by a 45 mg food pellet (P. J. Noyes, Lancaster,
NH), the rat was required to release the lever with RTs 600 ms. RTs
were measured in milliseconds as the time elapsing from the response
signal onset to lever release. Performance wasmeasured by recording the
number of correct and incorrect (nonrewarded) responses as either “pre-
mature,” corresponding to early withdrawal of the lever (before the onset
of the response signal), or “delayed,” when the lever was released after the
600 ms time limit. Each daily session ended after 100 trials. Premature
responses were recorded independently and were not limited. At the end
of training period, rats were tested for 7 consecutive days in theRT task to
measure preoperative baseline values before surgery. After a 7 d recovery
period, postoperative performance was recorded daily until day 60
postsurgery.
Surgery
The animals were anesthetized by systemic injection of xylazine (15 mg/
kg) and ketamine (100 mg/kg) and placed in a stereotaxic instrument
(David Kopf, Tujunga, CA) with the incisor bar positioned 3.0 mm
under the interaural line for surgical procedures based on the stereotaxic
coordinates (Paxinos and Watson, 2005). Lesioned animals received bi-
lateral injections of 6-hydroxydopamine hydrochloride (Sigma, Lyon,
France) (4g/l, 3l per side) in the dorsolateral striatum at the follow-
ing coordinates: anteroposterior (AP),0.2 mm; lateral (L),3.5 mm;
and dorsoventral (DV),4.8 mm according to bregma. The sham con-
trol group received the vehicle solution (ascorbic acid, 0.1% solution) at
the same coordinates. Injections were performed with a micropump set
at a flow rate of 0.33 l/min, as described in the injection procedure
section. In addition to 6-OHDA or vehicle injections, all animals were
implanted with 10mmbilateral stainless-steel guide cannulas (23 gauge)
positioned 3 mm above the injection site in the GP or the SNr at the
following coordinates: AP, 0.92 mm; L, 3.0 mm; and DV, 4 mm
from bregma for GP; and AP,5.5mm; L,2.2mm; andDV,5.4mm
frombregma for SNr. The guide cannulaswere then anchored to the skull
with four stainless-steel screws and dental cement. Stainless-steel wire
inlet cannulas (10 mm) were placed inside to prevent occlusion.
Injection procedure
The bilateral intrapallidal or intranigral injections were performed with
stainless-steel injector needles (13 mm, 30 gauge) inserted inside the
implanted guide cannulas and fitted so that they protruded 3mm below,
into the GP or the SNr area. The injectors were connected via a polyeth-
ylene catheter (Tygon; 0.25 mm, i.d.) to Hamiltonmicrosyringes (10l)
fitted to amicropump (CMA/100; CMA/Microdialysis, Stockholm, Swe-
den). The flow delivered by the pump was set at 0.166 l/min for a
volume of 0.5l/side. At the end of injection, injector needles were left in
place for 3 more minutes to allow the diffusion of the solution. Immedi-
ately afterward, inlet cannulas were replaced and the performance in the
RT task was recorded.
Drugs
6-Hydroxydopamine hydrochloride (Sigma) was dissolved in ascorbic
acid solution (0.1mg/ml in 0.9% saline) to prevent oxidation. Themixed
D1/D2 dopaminergic receptor antagonist haloperidol (haldol injectable
solution, 5 mg/ml; Janssen, Boulogne, France) was dissolved in physio-
logical 0.9% saline solution and injected systemically at a dose of 1mg/kg.
ACPT-I (Acher et al., 1997; Schann et al., 2006) and L-AP4 (Ascent Sci-
entific, Weston-Super-Mare, UK) were freshly dissolved in distilled wa-
ter and artificial CSF, respectively. (S)-3,4-Dicarboxyphenylglycine
(DCPG; Ascent Scientific) (Thomas et al., 2001) was dissolved in artifi-
cial CSF solution. (R,S)--Cyclopropyl-4-phosphonophenylglycine
(CPPG; Tocris, Bristol, UK) (Toms et al., 1996) and picrotoxin (Sigma)
were dissolved in 0.9% saline solution. All solutions were adjusted to pH
7 with NaOH 0.1N.
Experimental procedure
Catalepsy test. Male Wistar rats (n  94; 280–300 gm; Charles River)
were implanted with guide cannulas bilaterally above the GP or SNr at
the same coordinates used for the RT experiment. After a recovery pe-
riod, haloperidol (1 mg/kg) was administered 85 min before ACPT-I
(GP: 0, 1, 2.5 nmol/l; SNr: 0, 0.25, 1 nmol/l; n 5–7 per group) and
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the animals were tested in the horizontal bar test. A control group (n 9)
received a combination of systemic and intracerebral injections of vehicle
solutions. Catalepsy was measured immediately after ACPT-I (or vehi-
cle) central administration and every 10 min for the 1 h test. Additional
experiments were conducted to test the effect of ACPT-I in the SNr (0,
0.1, 0.25, 1 nmol/l; n  5–7 per group) in a control group with no
haloperidol. To control the selectivity of ACPT-I, the group III mGluR
antagonist CPPG or vehicle was coadministered 10 min before ACPT-I
into the GP (n  7 per group) or SNr (n  5–7 per group). Doses of
CPPG, 10-fold higher than ACPT-1, were selected on the basis of a pre-
vious study (Palucha et al., 2004). Considering the similar affinity of
ACPT-I for mGluR4 and mGluR8 subtypes (supplemental Fig. 1, avail-
able at www.jneurosci.org as supplemental material), we further tested
the behavioral effects of a highly potent mGluR8-selective agonist,
DCPG, injected in the GP (n 6) and SNr (n 7 per group) in another
group of rats.
Reaction-time task. Sham-operated (n  39) and dopamine-depleted
rats (6-OHDA; n  77) were tested in the RT task. To familiarize the
animals to the intracerebral injection procedure, each of them received a
vehicle injection into the GP (n 62) or the SNr (n 54) at day 18 after
surgery. Shamand 6-OHDAanimalswere divided into subgroups receiv-
ing four doses of ACPT-I (0, 1, 2.5, 5 nmol/l for GP and 0, 0.05, 0.1, 0.25
nmol/l for SNr) in a pseudorandom order following a Latin-square
design at postsurgical days 22, 26, 30, and 34. Lower doses of ACPT-I
injected into the GP (0, 0.1, 0.2, and 0.3 nmol/l) were tested in an
additional group of rats. After a washout period of 2 weeks, at postoper-
ative day 50, sham and lesioned animals selected from the above-
mentioned groups were injected into the GP or the SNr with the GABAA
receptor antagonist picrotoxin (0.165 or 0.033 nmol/l for the GP and
SNr, respectively). Another group of animals received picrotoxin at post-
operative day 26 as a first injection to verify the effects of manipulating
GABA transmission in sham and 6-OHDA-lesioned animals on RT per-
formance. Because the main effects of picrotoxin were very similar in the
two experimental conditions (e.g., first injection at day 26 or after
ACPT-I treatment at day 50), the performance of the animals was pooled
into a single experimental group. To compare the effects of ACPT-I to a
classical group III mGluR agonist, additional experiments were con-
ductedwith L-AP4,which displays a similar profile of activity on all group
III mGluRs as ACPT-I (supplemental Fig. 1, available at www.jneuro-
sci.org as supplemental material). L-AP4 was injected at day 26 after
surgery at the dose of 1 and 0.05 nmol/l for the GP and the SNr,
respectively.
Data and statistical analysis
Catalepsy test. Data were analyzed by using a multiple Kruskal–WallisH
test. Themedian latencywas calculated for each dose and for each 10min
period. Individual comparisons were performed using the nonparamet-
ric Mann–Whitney U test.
Reaction-time task. The effects of dopamine depletion and ACPT-I
injections onRTperformancewere evaluated on each variable (i.e., num-
ber of correct, delayed, premature responses and mean RTs) averaged
across each session. Because the premature responses were not limited in
the RT task paradigm, few animals (n  5) exhibiting 100 premature
responses/session were considered as outliers and excluded from the
analysis of this parameter. For preoperative and postoperative condi-
tions, we used four consecutive sessions before surgery [preoperative
(Pre)] and the four sessions corresponding to the performancemeasured
on the days before injection [postoperative (Post); e.g., days 21, 25, 29,
and 33]. Because there was no difference between the four sessions either
in the Pre or the Post conditions for any variable, the performance aver-
aged over four sessions was thus compared with that measured after
ACPT-I or vehicle injection into the GP or the SNr.We first analyzed the
effect of the order of injections between the different groups tested. The
subjects that did not receive all of the injections within a given order
according to the Latin-square design (loss of cannula for example) were
excluded from statistical analysis. If no effect of order was found, the
animals were pooled into one group. Data were then submitted to a
mixed-design ANOVA with different group (sham vs 6-OHDA) as the
between-subject factor and condition (Pre, Post, vehicle, dose 1, dose 2,
and dose 3 of ACPT-I) as the within-subject factor, as appropriate. In a
similar manner, the effects of picrotoxin and L-AP4 were compared with
one preoperative (the day before surgery) and postoperative session. Post
hocmultiple comparisons between groups were made using simple main
effects analysis and Fisher’s protected least significant difference (PLSD)
test, as appropriate.
Histology
At completion of behavioral testing, rats were deeply anesthetized and
killed by decapitation and brains were stored at 80°C until cryostat
sectioning. Brains coronal 10 m sections were collected (20°C) at the
level of the striatum, GP, and SNr using a cryostat apparatus (CM3050;
Leica, Nussloch, Germany). GP and SNr sections were stainedwith cresyl
violet to check the accuracy of injection sites. Only rats showing the
appropriate injection sites were used for data analysis. The extent of
6-OHDA lesions was verified by autoradiographic labeling of DA uptake
sites at striatal level using [ 3H]mazindol as a ligand in randomly selected
subjects of each group. Binding of [ 3H]mazindol was measured accord-
ing to the procedure described previously (Javitch et al., 1985). Briefly,
sections were first air-dried and rinsed for 5 min at 4°C in 50 mM Tris
buffer with 120 mM NaCl and 5 mM KCl. Then, the sections were incu-
bated for 40 min with 15 nM [3H]mazindol (specific activity 17 Ci/mM;
DuPont NEN, Boston, MA) in 50 mM Tris buffer containing 300 mM
NaCl and 5 mM KCl added with 0.3 mM desipramine to block the nor-
adrenaline transporter. The possible unspecific binding was determined
by incubating some sections in the same solution plus 30 mM benztro-
pine. Sections were rinsed twice for 3 min in the incubation medium
without mazindol and for 10 s in distilled water and were air dried.
Finally, the sections were left in contact for 21 d to a specific 3H-sensitive
film screen (Raytest, Courbevoie, France) to generate autoradiographs.
Results
Histology
The binding of [3H]mazindol to dopamine uptake sites in the
striatum as determined on coronal sections was used to delineate
the extent of dopamine depletion induced by bilateral striatal
6-OHDA injections (Fig. 1). The dopamine lesions were consis-
tently restricted to the dorsolateral part of the striatum at the
rostral level and extended more ventrally at more caudal levels
(end of the anterior commissure). As reported previously, striatal
6-OHDA infusions induce a 60% decrease in [3H]mazindol la-
beling in the dorsal area of the striatum compared with sham-
operated animals (Turle-Lorenzo et al., 2006), which fits with the
decrease of endogenous striatal DA contents assessed by HPLC
Figure 1. Binding of [ 3H]mazindol to dopamine uptake sites in the striatum. Photomicro-
graphs comparing [ 3H]mazindol labeling in striatal sections from a sham-operated animal and
abilaterally 6-OHDA-lesioned animal are shown. The lack ofmazindol binding shows the extent
of dopamine depletion in the dorsal striatummeasured at three different anteriority levels [AP,
0.48,0.12,0.48 mm related to bregma (Paxinos andWatson, 2005)]. Scale bar, 2 mm.
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(Amalric et al., 1995). Figure 2, A and B,
shows schematic reconstructions of cor-
rect injection sites in the GP and the SNr,
andC andD show the locations of injector
needles on frontal sections of representa-
tive subjects. Subjects with incorrect injec-
tion sites located outside the GP (n 10)
or the SNr (n  7) were excluded from
statistical analysis.
Effects of ACPT-I on
haloperidol-induced catalepsy
Globus pallidus
Haloperidol (1 mg/kg, i.p.) produced a
profound cataleptic state as shown by in-
crease in median latency to step down the
rod compared with controls ( p  0.01;
Mann–Whitney U test after a Kruskal–
Wallis test;H 132.26) (Fig. 3). Catalepsy
induced by haloperidol was significantly
antagonized by intrapallidal injection of
ACPT-I at the two doses tested ( p 0.01;
Mann–Whitney U test). Whereas ACPT-I
1 nmol/l induced a transient reversal of
catalepsy for the first 30min of testing, 2.5
nmol/l was effective for the total dura-
tion of the test and significantly different
from1nmol ( p 0.01;Mann–WhitneyU
test). The selective group III mGluR an-
tagonist CPPG (25 nmol/l), which had
no effect on its own, completely reversed
the anticataleptic effect of ACPT-I 2.5
nmol/l ( p  0.01; Mann–Whitney U
test).
The classical group III mGluR agonists
L-AP4 or ACPT-I show similar affinity for
mGluR4 and mGluR8 [EC50 values (mi-
cromolar): mGluR4, 0.5–1 and 7.2, and
mGluR8, 0.6 and 10.1 for L-AP4 and
ACPT-I, respectively]with higher concen-
trations required to activate mGluR7
(160–800 and 1200 M, respectively) (Acher et al., 1997; De
Colle et al., 2000; Schann et al., 2006). We therefore examined
whether DCPG, a selective mGluR8 agonist (Thomas et al.,
2001), could modify haloperidol-induced catalepsy. Because
DCPG is 100 times more potent than ACPT-I on mGluR8, but
has similar affinity for mGluR4, we used a 10-fold lower concen-
tration ofDCPG (0.1 nmol/l) comparedwith the effective doses
of ACPT-I to ascertain specific activation of mGluR8 subtype. At
that dose, DCPG did not reverse haloperidol-induced catalepsy
(Fig. 3), suggesting that the antiparkinsonian effects of ACPT-I in
the GP are not primarily mediated by mGluR8 subtypes.
Substantia nigra
In contrast to the effects observed in the GP, ACPT-I 1 nmol/l
only weakly reduced the haloperidol-induced catalepsy, whereas
0.25 nmol/l was ineffective ( p  0.01; Mann–Whitney U test
after Kruskal–Wallis test; H 114.44) (Fig. 4A). The effect pro-
duced by ACPT-I 1 nmol/l was reversed by CPPG 10 nmol/l,
which by itself did not modify haloperidol-induced catalepsy.
The selective mGluR8 agonist DCPG 0.1 nmol/l did not signif-
icantly modify haloperidol-induced catalepsy (Fig. 4A).
In control animals, which received vehicle of haloperidol (Fig.
4B), ACPT-I 1nmol/l was found to induce a weak but signifi-
cant cataleptic state for the first 20 min ( p 0.01; Mann–Whit-
neyU test after a Kruskal–Wallis test;H 85.26). This effect was
blocked by CPPG ( p 0.01; Mann–Whitney U test). Low doses
of ACPT-I (0.1 and 0.25 nmol/l) or CPPG alone did not pro-
duce any effect. DCPG 0.1 nmol/l induced a similar level of
catalepsy than that produced by ACPT-I 1 nmol/l ( p  0.01;
Mann–Whitney U test compared with vehicle).
6-OHDA lesion effects on RT performance
At completion of the training phase, all animals reached a preop-
erative level ranging from80 to 90 correct responses/session (cor-
responding to 10–20 delayed responses/session), with mean RTs
of 330–360ms.Whereas performance of sham-operated animals
was unchanged after surgery, 6-OHDA lesions impaired correct
performance in the various lesion groups (Figs. 5, 6). These def-
icits were characterized by a significant increase of delayed re-
sponses relative to preoperative levels (ANOVA, GP, F(1,38) 
38.25; SNr, F(1,36)  13.39; p  0.01). Mean RTs were signifi-
cantly lengthened (to 370–390 ms) after 6-OHDA lesions com-
paredwith preoperative levels (ANOVA,GP, F(1,38) 16.29; SNr,
F(1,36)  7.97; p  0.01). Moreover, performance of lesioned
animals measured during the postoperative period was signifi-
Figure 2. A,B, Schematic reconstruction of the injection sites in the globus pallidus (A) and the substantia nigra pars reticulata
(B) at different anteriority levels (AP, from0.36 to1.08mmand from4.56 to5.64mmrelated to bregma, for theGPand
the SNr, respectively). C, D, Photomicrographs of Nissl-stained sections showing representative injector needle placement in the
globus pallidus (C) and the substantia nigra pars reticulata (D). Scale bars: C, D, 1 mm. Injection sites for the animals injected
with ACPT-I; °injection sites for the animals injected with picrotoxin.
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cantly different from performance of sham-operated animals
(ANOVA, GP, F(1,28) 15.71 and 15.36; SNr, F(1,28) 8.56 and
5.25; p 0.05 for delayed responses and RTs, respectively). The
lesion-induced deficits were stable over time (up to postoperative
day 60) (data not shown). No significant effect of 6-OHDA le-
sions was found on premature responding whatever the groups
tested (Tables 1-3). Mean postoperative levels were similar to
preoperative performance both in sham and lesioned animals.
Effects of ACPT-I injection on RT performance
Globus pallidus
No significant effect of injection order for the various ACPT-I
doses tested according to a Latin-square designwas found for any
variable at any time postlesion, showing the stability of the be-
havioral effects over time. Low doses of ACPT-I (0.1, 0.2, 0.3
nmol/l) failed to attenuate the deficits induced by bilateral
6-OHDA lesions and did not modify performance of sham-
operated animals (data not shown). In contrast, the overall
ANOVA revealed that highest doses of ACPT-I significantly
modified the number of correct, delayed responses (ANOVA,
F(5,140) 4.55, p 0.01) andmeanRTs (ANOVA, F(5,140) 3.66,
p 0.01) in the 6-OHDA group, although it did not affect these
parameters in the sham group (Fig. 5). ACPT-I at 1, 2.5, and 5
nmol/l completely reversed the increase of both delayed re-
sponses and RTs compared with postoperative performance and
after vehicle injection ( p 0.05, Fisher’s PLSD test after signifi-
cant ANOVA, F(5,114)  6.61 and 4.55, respectively). Moreover,
ACPT-I induced a total recovery of preoperative performance
level, which returned to control group level. As shown in Table 1,
ACPT-I significantly modified the number of premature re-
sponses in sham-operated and 6-OHDA-lesioned rats (overall
main treatment effect ANOVA, F(5,115)  16.22, p  0.01).
Whereas ACPT-I at 1 nmol/l had no effect, 2.5 and 5 nmol/l
induced a marked increase in premature responses in the two
groups compared with preoperative and postoperative periods
Figure 3. Effects of ACPT-I, CPPG, and DCPG injections into the globus pallidus on
haloperidol-induced catalepsy. Eighty-fiveminutes after haloperidol administration (1mg/kg),
animals (n 5–7 per group) received intrapallidal injections of ACPT-I (0, 1, 2.5 nmol/l) or
the mGluR8-selective agonist DCPG (0.1 nmol/l), and catalepsy was measured immediately
and every 10 min for the 1 h testing. The group III mGluR antagonist CPPG (25 nmol/l) was
injected 10 min before ACPT-I or vehicle. The data are expressed as mean median latency
SEMduring the total durationof the test. *Significantly different fromcontrol group ( p0.05;
significant Mann–Whitney U test). #Significantly different from haloperidol group ( p 0.05;
significant Mann–Whitney U test).
Figure 4. Effects of ACPT-I, DCPG, and CPPG injections into the substantia nigra pars reticu-
lata on haloperidol-induced catalepsy. A, B, Animals (n 5–7 per group) received intranigral
injections of ACPT-I (0, 0.25, 1 nmol/l) or mGluR8-selective agonist DCPG (0.1 nmol/l) 85
min after haloperidol (1 mg/kg) administration (A) or after saline injection (B). Catalepsy was
measured immediately after intranigral injections and every 10 min for the 1 h testing. The
group III mGluR antagonist CPPG (10 nmol/l) was injected 10 min before ACPT-I or vehicle.
The data are expressed as mean median latency SEM during the total duration of the test.
*Significantly different from control group ( p  0.05; significant Mann–Whitney U test).
#Significantly different from haloperidol group ( p 0.05; significant Mann–Whitney U test).
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and to vehicle injections ( p  0.01, Fish-
er’s PLSD test after a significant ANOVA,
F(5,54) 7.94; F(5,84) 5.93 for sham and
lesioned animals, respectively). This in-
crease of premature responding could be
related to a nonspecific enhancement of
motor reactivity or attentional deficits.
Substantia nigra
In a preliminary experiment, we first
tested the effects of ACPT-I at a dose of 1
nmol/l. This dose produced a profound
akinesia, which prevented the animals
from performing the task. We therefore
completed another series of experiments
using lower doses. Figure 6 illustrates the
effects of ACPT-I (0.05, 0.1, and 0.25
nmol/l) injection into the SNr in sham
and lesioned animals. There was no signif-
icant effect of injection order for any vari-
able whatever the postoperative day. The
overall ANOVA performed on the num-
ber of delayed responses and mean RTs
revealed a significantmain “treatment” ef-
fect (ANOVA, F(5,140)  43.82 and 20.59,
respectively; p  0.01). In both sham-
operated and 6-OHDA-lesioned groups,
injection of vehicle into the SNr did not
significantly modify the performance
compared with the postoperative period.
At all doses tested, ACPT-I induced a dra-
matic increase in the number of delayed
responses in the sham and lesion groups
compared with preoperative and postop-
erative periods and after vehicle injection
( p  0.01, Fisher’s PLSD test after a sig-
nificant ANOVA; F(5,60)  14.69 and
F(5,108) 19.49 for sham and lesioned an-
imals, respectively). In line with this,
ACPT-I produced similar lengthening of
RTs in the two groups at all doses ( p 
0.01, Fisher’s PLSD test after a significant
ANOVA; F(5,60) 6.88 and F(5,108) 8.73
for sham and lesioned animals, respec-
tively). As shown in Table 2, ACPT-I did
not significantly modify the number of
premature responses in the two groups
compared with preoperative and postop-
erative periods and after vehicle injection.
Effects of L-AP4 injection on
RT performance
To compare the effects of ACPT-I with
those of a classical group III mGluR ago-
nist, an additional group of 6-OHDA-
lesioned rats was injected with L-AP4 either into the GP or the
SNr (Fig. 7). As found previously, 6-OHDA-induced lesions in-
creased the number of delayed responses and lengthened RTs
compared with preoperative period (ANOVA, GP, F(2,15) 7.11
and 3.78; SNr, F(2,21) 16.71 and 14.04, p 0.01, respectively).
Globus pallidus
As shown in Figure 7, L-AP4 1 nmol/l reversed the lesion-
induced deficits by reducing the number of delayed responses
and RTs compared with the postoperative period ( p  0.05,
Fisher’s PLSD). In addition, L-AP4 induced a nonsignificant in-
crease of premature responses (data not shown).
Substantia nigra
L-AP4 0.05 nmol/l induced a marked increase of delayed re-
sponses and RTs compared with preoperative and postoperative
periods ( p 0.05, Fisher’s PLSD) with no significant change of
premature responses.
Figure5. Effects of ACPT-I injections into the globus pallidus in the reaction-time task for sham (n 10) and 6-OHDA-lesioned
rats (n20). Performance is expressedby themeannumber of correct anddelayed trials SEMandmean SEM reaction times
in milliseconds. Performance is measured on different sessions: four preoperative sessions preceding the surgery (Pre) and four
postoperative sessions corresponding to the days before injection of ACPT-I (Post). ACPT-I (0, 1, 2.5, and 5 nmol/l) is injected at
postoperative days 22, 26, 30, and 34 following a Latin-square design, and the effects induced by the different doses of ACPT-I are
comparedwith the preoperative, postoperative, and control performance. *Significantly different frompreoperative performance
( p 0.05, Fisher’s PLSD test after significant ANOVA). #Significantly different from postoperative performance ( p 0.05,
Fisher’s PLSD test after significantANOVA). £Significantly different fromvehicle level ( p0.05, Fisher’s PLSD test after significant
ANOVA).
Figure 6. Effects of ACPT-I injection into the substantia nigra pars reticulata in the reaction-time task for sham (n 11) and
6-OHDA-lesioned rats (n 19). Performance is expressed by the mean number of correct and delayed trials SEM and by
mean SEM reaction times in milliseconds. ACPT-I (0, 0.05, 0.1, and 0.25 nmol/l) is injected at postoperative days 22, 26, 30,
and 34 following a Latin-square design, and the effects induced by the different doses of ACPT-I are compared with the preoper-
ative, postoperative, and control performance. *Significantly different from preoperative performance ( p 0.05, Fisher’s PLSD
test after significant ANOVA). #Significantly different from postoperative performance ( p 0.05, Fisher’s PLSD test after signif-
icant ANOVA). £Significantly different from vehicle level ( p 0.05, Fisher’s PLSD test after significant ANOVA).
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The effects induced by L-AP4 in theGPor the SNrwere similar
to those produced by the same doses of ACPT-I in the same site,
confirming the selectivity of ACPT-1 on group III mGluRs.
Effects of the GABAA antagonist picrotoxin injection on
RT performance
To determine whether the behavioral effects produced by group
III mGluR activation in the GP or SNr could be related to a
modulation of GABA transmission, we tested the effects pro-
duced by picrotoxin, a selective GABAA antagonist, in the same
locations. As previously found, 6-OHDA lesions increased the
mean number of delayed responses and lengthened RTs (GP,
ANOVA, F(1,10) 11.94 and 10.75; SNr, F(1,14) 9.78 and 10.41,
p  0.01, for delayed responses and mean RTs, respectively)
(Figs. 8, 9).
Globus pallidus
As shown in Figure 8, 0.165 nmol/l picrotoxin reversed the
lesion-induced deficits by decreasing the number of delayed re-
sponses and RTs compared with postoperative period ( p 0.05,
Fisher’s PLSD test after a significant ANOVA; F(2,15)  5.58,
F(2,15) 3.97, respectively). As observed previously with ACPT-I,
picrotoxin injection significantly increased the number of pre-
mature responses in lesioned animals compared with preopera-
tive and postoperative conditions (Table 3) ( p  0.01, Fisher’s
PLSD test after a significant ANOVA; F(2,15)  8.2). A similar
tendency was observed in sham-operated animals (Table 3) ( p
0.06).
Substantia nigra
Picrotoxin at 0.033 nmol/l induced a
dramatic increase of delayed responses
both in sham-operated and 6-OHDA le-
sioned animals compared with preopera-
tive and postoperative periods (Fig. 9)
( p  0.01, Fisher’s PLSD test after a sig-
nificant ANOVA; F(2,21)  12.1 and 12.9
for sham and lesioned groups, respec-
tively). In addition, RTs were significantly
lengthened after picrotoxin injection
( p  0.05, compared with preoperative
and postoperative levels, Fisher’s PLSD
test after a significant ANOVA; F(2,21) 
4.05, F(2,21) 12,59). Asmentioned in Ta-
ble 3, picrotoxin had no significant effect
on premature responses either in sham or
lesioned animals.
Discussion
The present study reveals that activation
of group IIImGluRs in theGP or SNrwith
agonists such as ACPT-I and L-AP4 produces opposite behavioral
effects in rat models of PD. Although the pallidal injection of
ACPT-I or L-AP4 has antiparkinsonian actions both in acute and
progressive rat models of the disease, the same compounds in-
jected at a 10-fold lower concentration in the SNr potentiate the
motor impairment in lesioned and control animals. In addition,
the GABAA antagonist picrotoxin injected into the GP or SNr
produces behavioral effects similar to those induced by group III
mGluRs agonists injected in the same locations.
The different potency ofACPT-I at group I, II, and IIImGluRs
shows a profile of activity strikingly similar to the classical ago-
nist, L-AP4, with a slightly weaker affinity (Acher et al., 1997;
Moldrich et al., 2003; Schann et al., 2006) (supplemental Fig. 1,
available at www.jneurosci.org as supplemental material). L-AP4
and ACPT-I exhibit similar potencies on mGluR4 and mGluR8
with lower affinity formGluR7 and no consistent effects on other
mGluRs (Acher et al., 1997; De Colle et al., 2000; Schann et al.,
2006). Our results show that equipotent doses of ACPT-I or
L-AP4 produced similar effects on RT performance and that
ACPT-I effects on catalepsy were fully reversed by CPPG, a selec-
tive group III mGluRs antagonist. Last, ACPT-I produces anti-
convulsant actions, anxiolytic effects, and analgesia, which are
thought to be mediated by group III mGluRs (Chapman et al.,
2001; Moldrich et al., 2003; Palucha et al., 2004; Goudet et al.,
2006). All this converges to show selective activation of group III
mGluRs by ACPT-I.
Group III mGluRs activation in the globus pallidus produces
antiparkinsonian action
Our findings that ACPT-I reverses haloperidol- and 6-OHDA-
induced akinesia are in agreementwith the antiparkinsonian actions
of group III mGluR agonists in pharmacological and lesion models
of PD (Marino et al., 2003;Valenti et al., 2003;MacInnes et al., 2004;
Konieczny et al., 2007).Our results extend these findings bydemon-
strating that dysfunction of glutamate activity at group III mGluRs
probably occurs early in the progression of the disease when DA
depletion is restricted to the dorsal striatum. According to the spe-
cific expression pattern of group III mGluRs in the BG (Testa et al.,
1994; Bradley et al., 1999a,b; Kosinski et al., 1999; Corti et al., 2002;
Messenger et al., 2002), ACPT-I and L-AP4 at low concentrations
may act primarily at mGluR4 and/or mGluR8 to produce their be-
Table 1. Effects of ACPT-I injection into the globus pallidus on the number of premature responses
ACPT-I (nmol/l)
Pre Post 0 1 2.5 5
Globus pallidus
Sham (n 10) 58.0 5.9 64.4 7.3 65.2 15.7 104.4 22.1 206.4 29.3*,**,*** 272.1 71.4*,**,***
6-OHDA (n 15) 64.7 15.6 64.6 13.6 60.4 10.6 122.8 23.2 184.4 32.8*,**,*** 176.5 38.1*,**,***
Values correspond to themean number of premature responsesSEMon different sessions: four sessions preceding the surgery (Pre) and four postoperative
sessions (Post) corresponding to the days before infusion of ACPT-I at various doses (days 22, 26, 30, and 34). *p 0.05, Fisher’s PLSD test, compared with
preoperative performance after significant ANOVA. **p 0.05, Fisher’s PLSD test, compared with postoperative performance after significant ANOVA. ***p
 0.05, Fisher’s PLSD test, compared with vehicle infusion after significant ANOVA.
Table 2. Effects of ACPT-I injection into the substantia nigra pars reticulata on the number of premature
responses
ACPT-I (nmol/l)
Pre Post 0 0.05 0.1 0.25
Substantia nigra
Sham (n 11) 57.4 14.9 77.9 15.0 65.4 15.0 54.0 9.9 63.4 17.3 61.4 14.8
6-OHDA (n 19) 60.2 11.3 70.7 8.8 57.6 11.0 72.1 14.8 73.0 10.3 85.2 15.7
Values correspond to themeannumber of premature responses SEMondifferent sessions: four sessions preceding the surgery (Pre) and four postoperative
sessions (Post) corresponding to the days before infusion of ACPT-I at various doses (days 22, 26, 30, and 34).
Table 3. Effects of picrotoxin injection into the globus pallidus or the substantia
nigra pars reticulata on the number of premature responses
Pre Post Picrotoxin
Globus pallidus
Sham (n 6) 38.2 12.1 49 12.4 221.5 104.8*,**
6-OHDA (n 6) 45 12 33.7 5.1 172.3 49.3*,**
Substantia nigra
Sham (n 8) 38.6 7.2 36.7 6.5 31.13 5.6
6-OHDA (n 8) 38.6 4.9 45 8.6 51.63 9.3
The values correspond to the mean number of premature responsesSEM recorded on different sessions of the
preoperative (Pre) or postoperative (Post) period. Postoperative days correspond to the sessions preceding the day
of picrotoxin injection into the GP or the SNr (0.165 and 0.033 nmol/l, respectively). *p 0.05, Fisher’s PLSD test,
compared with preoperative performance after significant ANOVA. **p 0.05, Fisher’s PLSD test, compared with
postoperative performance after significant ANOVA.
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havioral effects. Previous in vitro and ex vivo
studies reported that a selectivemGluR4 ag-
onist induces neuroprotec-
tion against 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine toxicity (Battaglia et al.,
2006) and potentiates L-AP4-induced inhi-
bition at striatopallidal synapse, whereas the
mGluR8 agonist DCPG had no effect
(Marino et al., 2003; Valenti et al., 2003). In
line with this, our results favor mGluR4-
mediated effects at GP level because DCPG
did not reverse haloperidol-induced
catalepsy.
At the pallidal level, electrophysiologi-
cal in vitro studies demonstrate that L-AP4
decreases GABAergic and glutamatergic
transmission at striatopallidal and sub-
thalamopallidal synapses, respectively
(Matsui and Kita, 2003; Valenti et al.,
2003). At a behavioral level, ACPT-I,
LAP-4, or picrotoxin injected into the GP
produce similar effects on RT perfor-
mance. Although this comparison only
provides indirect evidence, these results
suggest that the functional effects of
ACPT-I and L-AP4 may be related to a
modulation ofGABA activity in theGP. In
line with this suggestion, intrapallidal in-
jections of picrotoxin or bicuculline in-
duce anti-akinetic effects in various mod-
els of PD in rats (Ossowska et al., 1984;
Scheel-Kruger, 1984; Herrera-Marschitz
andUngerstedt, 1987;Maneuf et al., 1994;
Wisniecki et al., 2003). In contrast, intra-
pallidal injections of muscimol induce
catalepsy (Scheel-Kruger, 1984) and akinesia in the RT task
(Amalric and Koob, 1989). This hypothesis, which implies hypo-
activity of the GP in PD state (Albin et al., 1989; DeLong, 1990),
does not fit however with recent reconsideration of GP function
in the BG circuitry (Levy et al., 1997). The expression of the
GABA-synthesizing enzymeGAD67 is enhanced in the GP rather
than decreased after extensive unilateral DA denervation (Kin-
caid et al., 1992; Soghomonian and Chesselet, 1992; Soghomo-
nian et al., 1994; Nielsen and Soghomonian, 2003). In contrast,
pallidal expression of cytochrome oxidase subunit I (COI), a
metabolic index of neuronal activity, was not enhanced after par-
tial DA denervation (Oueslati et al., 2005). These discrepancies
might be explained by extent of DA denervation in the different
PD models and by the different markers of neuronal metabolic
activity. Nevertheless, whatever the basal level of GP activity, re-
duction of GABA transmission should increase its activity (Mat-
sumura et al., 1995) and ultimately influence the overall func-
tional output (Obeso et al., 2006).
Alternatively, group III mGluR agonists may also reduce glu-
tamatergic activity by presynaptic activation of autoreceptors on
subthalamopallidal synapses (Matsui and Kita, 2003), which
should ultimately produce opposite behavioral effect (e.g., en-
hancement of akinesia). Indirect functional evidence after palli-
dal NMDA receptors blockade argue in favor of this hypothesis.
Indeed, selective NMDA antagonists produce rigidity, catalepsy
(Turski et al., 1990), and akinesia in the RT task (Baunez and
Amalric, 1996).
Paradoxical effects of group III mGluR activation into the
substantia nigra pars reticulata
Group III mGluR activation in the SNr induces weak catalepsy in
control animals and further exacerbates 6-OHDA-induced defi-
cits. The doses of ACPT-I or L-AP4 required to produce behav-
ioral effects on RT were 10-fold lower than in the GP. This could
be attributable to either a different level of expression of mGluR
subtypes or a different involvement of the various subtypes to
produce these behavioral effects. Our results support the later
hypothesis, because both ACPT-I at 1 nmol and the selective
mGluR8 agonist DCPG at 0.1 nmol produce a similar cataleptic
level in control animals. Moreover, at a same concentration,
ACPT-I has no effect whereas DCPG still produces catalepsy,
suggesting that mGluR8 rather than mGluR4 in the SNr are me-
diating these parkinsonian symptoms. However, characteriza-
tion of the receptor subtypes involved await for development of
selective compounds appropriate for in vivo studies.
In haloperidol-treated rats, the same dose of ACPT-I slightly
reversed akinesia in agreement with a recent finding published
during the course of the present study (Konieczny et al., 2007).
Similar results were found in reserpine model of PD with L-SOP
(L-serine-O-phosphate), another group III agonist (MacInnes et
al., 2004). The differential effects produced by ACPT-I in control
animals or after haloperidol treatment in the present study may
be related to recent evidence demonstrating that dopaminemod-
ulates group III mGluR function in the SNr (Wittmann et al.,
2002). Indeed, in vitro experiments conducted in reserpine or
haloperidol model of PD demonstrate that whereas action of
Figure 7. Effects of L-AP4 injection into the globus pallidus (n 6) or the substantia nigra pars reticulata (n 8) in the
reaction-time task for 6-OHDA-lesioned rats. Performance is expressed by the mean number of correct and delayed trials SEM
and by mean SEM reaction times in milliseconds. Performance is measured on one preoperative session (Pre), one postopera-
tive session corresponding to the day before injection of L-AP4 (Post). L-AP4 (1 and 0.05 nmol/l for the GP and SNr, respectively)
is injected at postoperative day 26. *Significantly different from preoperative performance ( p 0.05, Fisher’s PLSD test after
significant ANOVA). #Significantly different from postoperative performance ( p  0.05, Fisher’s PLSD test after significant
ANOVA).
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group IIImGluR agonist on autoreceptors
located on subthalamonigral nerve termi-
nals remains functional, their action on
heteroreceptors at the striatonigral syn-
apse is dramatically reduced (Wittmann et
al., 2002). This suggests that, in the acute
model of PD, the prominent action of
group III mGluR agonists in the SNr is to
primarily decrease overactive subthalam-
onigral glutamate activity, ultimately lead-
ing to reversal of akinesia. In contrast, in
the 6-OHDA-lesion model of PD and in
basal condition, group III mGluR agonists
could preferentially act on inhibitory
striatonigral synapses. In line with this,
GABAA receptors blockade in the SNr
produces akinesia in the RT task. Accord-
ingly, the increase ofCOI expression in the
SNr was positively correlated with the
magnitude of akinesia (Breysse et al.,
2002; Oueslati et al., 2005), suggesting a
specific involvement of this structure in
the expression of akinetic deficits. Any ad-
ditional reduction of GABA release in the
SNr would thus enhance its activity and
contribute to impair motor function as
predicted by the canonical model of BG
circuitry in PD (Albin et al., 1989; De-
Long, 1990). Consistent with this, intrani-
gral injections of GABAA receptor antago-
nists produce motor impairment in a
lever-pressing task (Correa et al., 2003)
and catalepsy (Scheel-Kruger, 1984), sug-
gesting that group III agonists could pro-
duce their paradoxical effects by reducing
GABA activity. In contrast, NMDA recep-
tor blockade in the SNr increases locomo-
tor activity (Klockgether andTurski, 1990;
Koch et al., 2000) and facilitates move-
ment initiation by decreasing RTs
(Baunez and Amalric, 1996). The akinetic
deficits induced by activation of group III
mGluRs in the SNr in the partial 6-OHDA
model of PD is likely to be caused by an
additional decrease of GABAergic neuro-
transmission. However, a decrease of glu-
tamate transmission cannot be ruled out
in other models of extensive DA
denervation.
Conclusion
Together, our results emphasize the role of
group III mGluRs in the GP and SNr in
modulating motor processes in both con-
trol and parkinsonian rats, presumably by
an indirect action on GABAergic neuro-
transmission. The opposite behavioral ef-
fects produced by activation of group III
mGluR in the GP and the SNrmay be me-
diated by different receptor subtypes. In
agreement with previous studies (Marino
et al., 2003; Valenti et al., 2003), our results
suggest a role for mGluR4 rather than
Figure 9. Effects of picrotoxin (0.033 nmol/l) injection into the SNr in the reaction-time task for sham (n 9) and 6-OHDA-
lesioned rats (n 8). Performance is expressed by themeannumber of correct anddelayed trials SEMandby themean SEM
reaction times inmilliseconds. Performance ismeasuredonpreoperative andpostoperative sessions andafter picrotoxin injection.
*Significantly different from preoperative performance ( p 0.05, Fisher’s PLSD test after significant ANOVA). #Significantly
different from postoperative performance ( p 0.05, Fisher’s PLSD test after significant ANOVA).
Figure8. Effects of picrotoxin (0.165nmol/l) injection into theglobuspallidus in the reaction-time task for sham(n6) and
6-OHDA-lesioned rats (n 6). Performance is expressed by the mean number of correct and delayed trials SEM and by the
mean SEM reaction times in milliseconds. Performance is measured on one preoperative session (Pre), one postoperative
session (Post) corresponding to the day before picrotoxin injection (day 26). *Significantly different from preoperative perfor-
mance ( p0.05, Fisher’s PLSD test after significantANOVA). #Significantlydifferent frompostoperativeperformance ( p0.05,
Fisher’s PLSD test after significant ANOVA).
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mGluR8 in normalizing BG activity and question therefore the
efficacy of non-subtype-selective group III agonists as an antipar-
kinsonian strategy in the early stage of PD.
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